NMNAT3 deficiency: a novel red blood cell enzymopathy causing hemolysis by altering NAD levels and glycolysis

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We describe, to our knowledge, the first case of nicotinamide mononucleotide adenylyl transferase 3 (NMNAT3) deficiency, a novel red cell enzymopathy that causes reduced NAD levels and mild hemolytic anemia, which improved upon NAD precursor supplementation. We therefore propose testing for NMNAT3 variants in unexplained hereditary hemolytic anemia.

Original languageEnglish
Pages (from-to)3246-3249
JournalBlood
Volume146
Issue number26
Early online date16 Oct 2025
DOIs
Publication statusPublished - 25 Dec 2025

Fingerprint

Dive into the research topics of 'NMNAT3 deficiency: a novel red blood cell enzymopathy causing hemolysis by altering NAD levels and glycolysis'. Together they form a unique fingerprint.

Cite this